Literature DB >> 25760201

Race influences stage-specific survival in gastric cancer.

J Harrison Howard1, Jason M Hiles, Anna M Leung, Stacey L Stern, Anton J Bilchik.   

Abstract

Gastric adenocarcinoma studies show improved survival for Asians but have not reported stage-specific overall survival (OS) or disease-specific survival (DSS) by race. The Surveillance, Epidemiology and End Results database was queried for cases of gastric adenocarcinoma between 1998 and 2008. We evaluated OS and DSS by race and stage. Number of assessed lymph nodes was compared among surgical patients. Of 49,058 patients with complete staging data, 35,300 were white, 7709 were Asian, and 6049 were black. Asians had significantly better OS for all stages (P < 0.001) and significantly better DSS for Stages I (P < 0.0001) and II (P = 0.0006). As compared with blacks, whites had significantly better DSS for Stages I (P < 0.0001), II (P = 0.0055), III (P = 0.0165), and IV (P < 0.0001). Among the 28,133 (57%) surgical patients, average number of evaluated lymph nodes was highest for Asians (P < 0.0001). Among surgical patients with 15 or more nodes evaluated, DSS was worse in blacks with Stage I disease (P < 0.05). Blacks with gastric adenocarcinoma have a worse DSS, which disappears when surgical treatment includes adequate lymphadenectomy. Race-associated survival differences for gastric adenocarcinoma might simply reflect variations in surgical staging techniques and socioeconomic factors.

Entities:  

Mesh:

Year:  2015        PMID: 25760201

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  13 in total

1.  Ethnicity-related differences in tumor immunity: a new possible explanation for gastric cancer prognostic variability?

Authors:  Daniele Marrelli; Karol Polom; Franco Roviello
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-16

2.  Examining the gastric cancer survival gap between Asians and whites in the United States.

Authors:  Hongbin Jin; Paulo S Pinheiro; Karen E Callahan; Sean F Altekruse
Journal:  Gastric Cancer       Date:  2016-11-19       Impact factor: 7.370

3.  Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.

Authors:  Kensei Yamaguchi; Kazumasa Fujitani; Fumio Nagashima; Yasushi Omuro; Nozomu Machida; Tomohiro Nishina; Toshiko Koue; Mika Tsujimoto; Kaijiro Maeda; Taroh Satoh
Journal:  Gastric Cancer       Date:  2018-03-05       Impact factor: 7.370

4.  Evaluating Dissemination of Adequate Lymphadenectomy for Gastric Cancer in the USA.

Authors:  Anthony M Villano; Alexander Zeymo; James McDermott; Andrew Crocker; Jay Zeck; Kitty S Chan; Nawar Shara; Sunnie Kim; Waddah B Al-Refaie
Journal:  J Gastrointest Surg       Date:  2019-02-20       Impact factor: 3.452

5.  It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors.

Authors:  Patrick W Underwood; Andrea N Riner; Dan Neal; Miles E Cameron; Anastasiya Yakovenko; Sushanth Reddy; John Bart Rose; Steven J Hughes; Jose G Trevino
Journal:  J Surg Oncol       Date:  2021-09-09       Impact factor: 2.885

6.  Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014.

Authors:  Naruhiko Ikoma; Janice N Cormier; Barry Feig; Xianglin L Du; Jose-Miguel Yamal; Wayne Hofstetter; Prajnan Das; Jaffer A Ajani; Christina L Roland; Keith Fournier; Richard Royal; Paul Mansfield; Brian D Badgwell
Journal:  Cancer       Date:  2018-02-02       Impact factor: 6.860

7.  Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.

Authors:  Elke J A H van Beek; Jonathan M Hernandez; Debra A Goldman; Jeremy L Davis; Kaitlin McLaughlin; R Taylor Ripley; Teresa S Kim; Laura H Tang; Jaclyn F Hechtman; Jian Zheng; Marinela Capanu; Nikolaus Schultz; David M Hyman; Marc Ladanyi; Michael F Berger; David B Solit; Yelena Y Janjigian; Vivian E Strong
Journal:  Ann Surg Oncol       Date:  2018-05-03       Impact factor: 5.344

8.  Development and external validation of a prognostic nomogram for gastric cancer using the national cancer registry.

Authors:  Jianjun Liu; Qirong Geng; Zhimin Liu; Shangxiang Chen; Jing Guo; Pengfei Kong; YingBo Chen; Wei Li; Zhiwei Zhou; Xiaowei Sun; Youqing Zhan; Dazhi Xu
Journal:  Oncotarget       Date:  2016-06-14

9.  Development and validation of a nomogram to individually predict survival of young patients with nonmetastatic gastric cancer: A retrospective cohort study.

Authors:  Chaorui Wu; Nianchang Wang; Hong Zhou; Tongbo Wang; Dongbing Zhao
Journal:  Saudi J Gastroenterol       Date:  2019 Jul-Aug       Impact factor: 2.485

10.  Differential networking meta-analysis of gastric cancer across Asian and American racial groups.

Authors:  Wentao Dai; Quanxue Li; Bing-Ya Liu; Yi-Xue Li; Yuan-Yuan Li
Journal:  BMC Syst Biol       Date:  2018-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.